Page last updated: 2024-11-12

ym 155

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sepantronium bromide : An organic bromide salt consisting of sepantronium cations and bromide anions. It has been found to selectively inhibit survivin (BIRC5) gene promoter activity and to down-regulate survivin in vitro, so leading to induction of apoptosis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11178236
CHEMBL ID2105734
CHEBI ID139608
SCHEMBL ID727997
SCHEMBL ID16584072
MeSH IDM0514870

Synonyms (58)

Synonym
sepantronium (bromide)
HY-10194
sepantronium bromide
ym-155
ym 155
3-(2-methoxyethyl)-2-methyl-4,9-dioxo-1-(pyrazin-2-ylmethyl)-4,9-dihydro-1h-naphtho[2,3-d]imidazol-3-ium bromide
bromure de sepantronium
sepantronii bromidum
CHEBI:139608
1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1h-naphtho[2,3-d]imidazol-3-ium bromide
bromuro de sepantronio
781661-94-7
FT-0660380
YM155 ,
sepantronium bromide (jan/usan)
D10164
sepantronium bromide [usan:inn]
1h-naphth(2,3-d)imidazolium, 4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazinylmethyl)-, bromide
7h5q4j1cm5 ,
unii-7h5q4j1cm5
BCPP000007
CS-0336
S1130
CHEMBL2105734
1h-naphth[2,3-d]imidazolium, 4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(2-pyrazinylmethyl)-, bromide
4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(2-pyrazinylmethyl)-1h-naphth[2,3-d]imidazolium bromide
SCHEMBL727997
MLS006010288
smr004701357
sepantronium bromide [jan]
sepantronium bromide [usan]
sepantronium bromide [inn]
1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-((pyrazin-2-yl)methyl)-4,9-dihydro-1h-naphtho(2,3-d)imidazolium bromide
sepantronium bromide [who-dd]
1h-naphth(2,3-d)imidazolium, 4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(2-pyrazinylmethyl)-, bromide (1:1)
DTXSID90228817
ym155 (sepantronium bromide)
AC-26890
SCHEMBL16584072
J-514184
HMS3654A08
mfcd11983133
3-(2-methoxyethyl)-2-methyl-4,9-dioxo-1-(pyrazin-2-ylmethyl)naphtho[2,3-d]imidazol-1-ium bromide
SW219422-1
3-(2-methoxyethyl)-2-methyl-4,9-dioxo-1-(pyrazin-2-ylmethyl)-4,9-dihydro-1h-naphtho[2,3-d]imidazol-3-ium bromide.
EX-A2187
ym-155; sepantronium bromide
AS-17057
BCP01864
AMY10848
1h-naphth[2,3-d]imidazolium,4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(2-pyrazinylmethyl)-,bromide (1:1)
CCG-264831
Q27268284
1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione;bromide
bdbm50468263
1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-[(pyrazin-2-yl)methyl]-1h,4h,9h-naphtho[2,3-d]imidazol-3-ium bromide
EN300-7406819
Z2037281428
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
survivin suppressantAn apoptosis inducer that works by selectively inhibiting survivin (BIRC5) gene promoter activity so as to down-regulate survivin, a protein that inhibits apoptosis, so leading to induction of apoptosis.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic bromide salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)2.47000.00022.45859.9600AID1884031
Serine/threonine-protein kinase PAK 1Homo sapiens (human)IC50 (µMol)0.50000.00020.30012.5000AID1424481
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
MAPK cascadeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of protein phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
exocytosisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of cell population proliferationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of cell migrationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of microtubule polymerizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
wound healingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
hepatocyte growth factor receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
ephrin receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
branching morphogenesis of an epithelial tubeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase PAK 1Homo sapiens (human)
negative regulation of cell proliferation involved in contact inhibitionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of microtubule nucleationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein localization to cytoplasmic stress granuleSerine/threonine-protein kinase PAK 1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
small GTPase bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
collagen bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
gamma-tubulin bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ruffleSerine/threonine-protein kinase PAK 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
chromosomeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin filamentSerine/threonine-protein kinase PAK 1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
focal adhesionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
intercalated discSerine/threonine-protein kinase PAK 1Homo sapiens (human)
Z discSerine/threonine-protein kinase PAK 1Homo sapiens (human)
lamellipodiumSerine/threonine-protein kinase PAK 1Homo sapiens (human)
axonSerine/threonine-protein kinase PAK 1Homo sapiens (human)
dendriteSerine/threonine-protein kinase PAK 1Homo sapiens (human)
nuclear membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
ruffle membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1884032Antiviral activity against SARS-CoV-2 nCoV-2019BetaCoV/Wuhan/WIV04/2019 infected in African green monkey Vero E6 cells assessed as viral growth inhibition pretreated for 1 hr followed by infection at MOI of 0.01 and replacement of fresh medium containing 2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1424481Inhibition of PAK1 in human A549 cells2017European journal of medicinal chemistry, Dec-15, Volume: 142From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1541833Cytotoxicity against CHOK1 cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter 96 aqueous one solution assay
AID1424482Antiangiogenic activity in HUVEC2017European journal of medicinal chemistry, Dec-15, Volume: 142From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1541831Antimalarial activity against asexual stage of Plasmodium falciparum Dd2 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs under hypoxic condition by Hoechst 33342 staining based flow cytometry
AID1770532Resistance index, ratio of IC50 for antiproliferation activity against human MDA-MB-435/LCC6MDR cells to IC50 for antiproliferation activity against human MDA-MB-435 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold.
AID1541832Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs under hypoxic condition by Hoechst 33342 staining based flow cytometry
AID1884033Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1424460Growth inhibition of human A549 cells2017European journal of medicinal chemistry, Dec-15, Volume: 142From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1770531Antiproliferative activity against human MDA-MB-435/LCC6MDR cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold.
AID1489178Cytotoxicity against human DU145 cells by MTT assay2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway.
AID1424480Antitumor activity against human PC3 cells wenografted in mouse assessed as inhibition of tumor growth at 3 mg/kg/day2017European journal of medicinal chemistry, Dec-15, Volume: 142From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1489179Cytotoxicity against human PC3 cells by MTT assay2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway.
AID1770527Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold.
AID1884031Inhibition of full-length SARS-CoV-2 papain-like protease (1564 to 1878 residues) expressed in Escherichia coli Rosetta (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by multimode plate reader analysis2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1424483Antiangiogenic activity in chicken chorioallantoic membrane assessed per egg2017European journal of medicinal chemistry, Dec-15, Volume: 142From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.26 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index47.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]